Safety and efficacy of ezetimibe monotherapy in 1624 primary hypercholesterolaemic patients for up to 2 years

International Journal of Clinical Practice

Volumn 62, Issue 9, 2008, Pages 1332-1336

  Dujovne, C A ^a   Suresh, R ^b   McCrary Sisk, C ^b   Maccubbin, D ^b   Strony, J ^b   Veltri, E ^b  

^a Kansas Foundation for Clinical Pharmacology   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADULT; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUSCULOSKELETAL PAIN; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINUSITIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED;

EID: 49349107489     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01798.x     Document Type: Article

References (16)

1. National Center for Health Statistics. National Health and Nutrition Examination Survey III (NHANES III), 1988-1994 [CD-ROM]. Hyattsville, MD: National Center for Health Statistics, 1994.
2. American Heart Association. Heart Disease and Stroke Statistics Update. Dallas, TX: American Heart Association, 2006.
3. Castelli WP. Epidemiology of coronary heart disease: the Framingham Study. Am J Med 1984 76: 4 12.
4. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. Ann Intern Med 1971 74: 1 12.
5. Verschuren WMM, Jacobs DR, Bloemberg BPM et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures: Twenty-five-year follow-up of the Seven Countries Study. JAMA 1995 274: 131 6.
6. Stamler J, Wentworth D, Neaton JD, for the MRFIT Research Group. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986 256: 2823 8.
7. van Heek M, France CF, Compton DS et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 1997 283: 157 63.
8. van Heek M, Farley CF, Compton DS et al. Comparison of the activity and disposition of the novel cholesterol inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 2000 129: 1748 54.
9. van Heek M, Farley C, Compton DS, Hoos L, Davis HR. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol 2001 134: 409 17.
10. Van Heek M, Farley C, Compton DS, Hoos LM, Smith-Torhan A, Davis HR. Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats. Br J Pharmacol 2003 138: 1459 64.
11. Altmann SW, Davis HR, Zhu LJ et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004 303: 1201 4.
12. Garcia-Calvo M, Lisnock J, Bull HG et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci 2005 102: 8132 7.
13. Dujovne CA, Ettinger MP, McNeer F et al., for the Ezetimibe Study Group. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002 90: 1092 7.
14. Knopp RH, Gitter H, Truitt T et al., for the Ezetimibe Study Group. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003 24: 729 41.
15. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993 269: 3015 23.
16. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001 285: 2486 97.